| Literature DB >> 28003323 |
Peixing Wan1, Wenru Su1, Yehong Zhuo1.
Abstract
Long non-coding RNAs (lncRNAs) are remarkably powerful, flexible and pervasive cellular regulators. With the help of cheaper RNA-seq, high-throughput screening of lncRNAs has become widely applied and has identified large numbers of specific lncRNAs in various physiological or pathological processes. Vision is known to be a complex and vital perception that comprises 80% of the sensory information we receive. A consensus has been reached that normal visual maintenance and impairment are primarily driven by gene regulation. Recently, it has become understood that lncRNAs are key regulators in most biological processes, including cell proliferation, apoptosis, differentiation, immune responses, oxidative stress and inflammation. Our review is intended to provide insight towards a comprehensive view of the precise modulation of lncRNAs in visual maintenance and impairment. We also highlight the challenges and future directions in conducting lncRNA studies, particularly in patients whose lncRNAs may hold expanded promise for diagnostic, prognostic and therapeutic applications. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.Entities:
Keywords: Long noncoding RNAs; Ocular diseases; Visual impairment; Visual maintenance; Visual system
Mesh:
Substances:
Year: 2016 PMID: 28003323 PMCID: PMC5502309 DOI: 10.1136/jmedgenet-2016-104266
Source DB: PubMed Journal: J Med Genet ISSN: 0022-2593 Impact factor: 6.318
Figure 1Landscape of long non-coding RNAs (lncRNAs) expression in visual maintenance. Visual system consists two parts: (A) Refracting media, including cornea, aqueous humour, lens and vitreous body. (B) Photosensitive system mainly composed of retina and optic nerve connecting with visual centre. Overview of the related lncRNAs in visual system was displayed in the lower half of the figure.
The role of long non-coding RNAs (lncRNAs) in the precise regulation of visual maintenance
| Official symbol | Also known as | Genomic location | Cell specific | Function |
|---|---|---|---|---|
| Six3os1 | Rncr1; Six3os; D17Mgi26; E130112H22Rik | 17 E4 | Retinal progenitors | Six3os1 was the first identified lncRNA that coeffect with its coding gene to play an important role in retinal development |
| MIAT | RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00066; lncRNA-MIAT | 22q12.1 | Progenitors and retinal precursor cells | MIAT plays a critical role in regulating mammalian retinal cell fate specification |
| BB283400 | Rncr4; BF465573 | Chromosome 6 | Retina | BB283400 was a retina-specific lncRNA that controls the uniformity of various retina layers |
| TUG1 | TI-227H; LINC00080; NCRNA00080 | 22q12.2 | Rod photoreceptors | TUG1 is necessary for the proper formation of photoreceptors in the developing rodent retina |
| Vax2OS | Vas2os; Vax2os1; Vax2os2 | 6 C3 | Photoreceptor progenitor cells | Vax2os is involved in the control of cell cycle progression of photoreceptor progenitor cells in the ventral retina |
| ENSMUST0000013486 | – | – | Photoreceptor phagocytosis | ENSMUST0000013486c is critical for circadian gene expression |
| H19 | ASM; BWS; WT2; ASM1; D11S813E; LINC00008; NCRNA00008 | 11p15.5 | – | H19 was reported to be female-biased specifically in the female mouse eye |
Figure 2Long non-coding RNAs (lncRNAs) in various kinds of visual impairment. This figure displayed lncRNAs in most visual impairments mentioned in this article, including (A) blepharophimosis, ptosis and epicanthus inversus syndrome (BPES), (B) age-related cataract, (C) glaucoma, (D) proliferative vitreoretinopathy (PVR), (E) uveal melanoma, (F) retinoblastoma, (G) age-related macular degeneration (AMD), (H) retinal neurodegeneration, (I) retinopathy of prematurity (ROP) and (J) diabetic retinopathy (DR).
The role of long non-coding RNAs (lncRNAs) in various kinds of visual impairment
| Official symbol | Also known as | Genomic location | Related disease | Alteration | Function |
|---|---|---|---|---|---|
| CRNDE | CRNDEP; PNAS-108; lincIRX5; LINC00180; NCRNA00180 | 16q12.2 | Uveal | Dys | CRNDE were associated with good prognosis via epigenetic mechanisms, particularly through histone methylation or demethylation by the PRC2 or CoREST complexes. |
| LINC-ROR | ROR; lincRNA-RoR | 18q21.31 | Uveal | Upregulation | LINC-ROR acts as an oncogenic lncRNA, activating the TESC promoter by repelling the histone G9A methyltransferase and promoting the release of histone H3K9. Suppression of ROR could reduce tumour growth and metastasis as reported. |
| BANCR | LINC00586 | Chr 9 | Retinoblastoma | Up | BANCR is overexpressed and associated with tumour size, choroidal invasion, and optic nerve invasion. Moreover, patients with high levels of lncRNA BANCR expression had poorer survival than those with lower levels of lncRNA BANCR expression. |
| PISRT1 | NCRNA00195 | 3q23 | BPES | Dys | PISRT1 deletion could be involved in FOXL2 regulation and constitutes the smallest deletion described in a female with BPES. |
| LINC00237 | NCRNA00237 | 20p11.23 | MOMO | – | LINC00237 was expressed in lymphocytes of control individuals while normal transcripts were absent in lymphocytes of our MOMO patient. |
| MALAT1 | HCN; NEAT2; PRO2853; mascRNA; LINC00047; NCRNA00047 | 11q13.1 | Diabetic | Up | MALAT1 downregulation could obviously ameliorate DR by functioning as a competing endogenous RNA in the regulation of VEGF levels through miR-150-5p. |
| Retinopathy of prematurity | Up | Knocking down of MALAT1 tips the balance from a proliferative to a migratory endothelial cell phenotype in vitro, and its genetic deletion restrains vascular growth in vivo. | |||
| Retinal | Up | MALAT1 knockdown reduces reactive gliosis, Müller cell activation, and RGC survival in vivo and in vitro. MALAT1 regulates Müller and RGC function through CREB signalling. | |||
| Proliferative vitreoretinopathy | Up | MALAT1 related to RPE proliferation and migration, promotion of ERM formation, and PVR pathogenesis. MALAT1 upregulation appeared in the cellular and plasma fraction of peripheral blood in PVR patients as well and obviously reduced after PVR operation. | |||
| rs9362054 | – | Chr 6 | Diabetic | Dys | Top signal of DR susceptibility loci. |
| Vax2os | Vas2os; Vax2os1; Vax2os2 | 6 C3 | Ocular | Up | Vax2os significantly upregulated in the aqueous humour of patients with CNV AMD and murine ocular neovascular models. |
| NR_033585 | – | – | Corneal | Up | The lncRNA NR_033585 was significantly upregulated in vascularised corneas and presented a similar expression pattern as pro-angiogenic factors. |
| Chr8:129102060–129109035 | – | – | Corneal | Down | lincRNA chr8:129102060–129109035 reverse strand was found to be markedly downregulated in vascularised corneas. |
| CDKN2B-AS1 | ANRIL; p15AS; PCAT12; CDKN2BAS; CDKN2B-AS; NCRNA00089 | 9p21.3 | Glaucoma | Dys | CDKN2B-AS1 is the genetic susceptibility locus for glaucoma, influencing the nearby CDKN2A and CDKN2B genes via regulatory mechanisms, which can influence cell proliferation and senescence. |
| LOXL1-AS1 | – | 15q24.1 | Exfoliation | Dys | LOXL1-AS1 manipulates the activity of promoter in LOXL1 region. |
| MIAT | RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00066; lncRNA-MIAT | 22q12.1 | Age-related | Up | MIAT knockdown could repress TNF-α-induced abnormal proliferation and migration of HLECs, by acting as a ceRNA and formed a feedback loop with Akt and miR-150-5p. |
| MEG3 | GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00023 | 14q32 | Diabetic | Down | MEG3 knockdown aggravates retinal vessel dysfunction in vivo, and also regulates retinal endothelial cell proliferation, migration and tube formation in vitro. |
| Retinoblastoma | Down | MEG3 is significantly downregulated and that the reduced expression is associated with a poor prognosis among patients with retinoblastoma. |
AMD, age-related macular degeneration; BPES, blepharophimosis, ptosis and epicanthus inversus syndrome; CNV, choroidal neovascularisation; HLEC, human lens epithelial cell; RPE, retinal pigmented epithelium; TNF-α, tumour necrosis factor α; VEGF, vascular endothelial growth factor.